Liraglutide
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Novo Nordisk · Phase 2 · Completed · Enrollment 834
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- Placebo + Metformin
- MEDI0382 100 mcg
- MEDI0382 200 mcg
- MEDI0382 300 mcg
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| MEDI0382 low dose + Metformin | n/r | n/r | n/r | n/r |
| MEDI0382 mid dose + Metformin | n/r | n/r | n/r | n/r |
| MEDI0382 high dose + Metformin | n/r | n/r | n/r | n/r |
| Placebo + Metformin | 3% | n/r | n/r | n/r |
| Liraglutide + Metformin | n/r | n/r | n/r | n/r |
| MEDI0382 100 mcg | 18% | n/r | n/r | n/r |
| MEDI0382 200 mcg | 65% | n/r | n/r | n/r |
| MEDI0382 300 mcg | 92% | n/r | n/r | n/r |
Not shown
- MEDI0382 low dose + Metformin: endpoint not reported
- MEDI0382 mid dose + Metformin: endpoint not reported
- MEDI0382 high dose + Metformin: endpoint not reported
- Liraglutide + Metformin: endpoint not reported